Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.46 |
| ▸ | BAD | Q92934 | 1/20 | 0.46 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.44 |
| ▸ | XDH | P47989 | 2/20 | 0.44 |
| ▸ | NR3C2 | P08235 | 4/20 | 0.42 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.41 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.41 |
| ▸ | PGR | P06401 | 1/20 | 0.41 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.40 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.40 |
| ▸ | KDM1A | O60341 | 1/20 | 0.40 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.39 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.39 |
| ▸ | ESR1 | P03372 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | TTR | P02766 | 1/20 | 0.39 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10063771 | 0.87 | SLC22A12 (0.44) | SLC22A12ADORA1 | |
| SCHEMBL10064208 | 0.85 | HPGD (0.43) | — | |
| SCHEMBL10064017 | 0.84 | SLC22A12 (0.39) | SLC22A12NR3C2KDM1AESR1CNR2 | |
| SCHEMBL10064307 | 0.83 | SLC22A12 (0.39) | SLC22A12NR3C2ESR1TTR | |
| SCHEMBL10064301 | 0.83 | HTR5A (0.43) | — | |
| SCHEMBL617022 | 0.81 | TTR (0.45) | SLC22A12KDM1ACNR2TTR | |
| SCHEMBL10063756 | 0.79 | SLC22A12 (0.48) | SLC22A12NR3C2KDM1ACSNK2A2CSNK2B | |
| SCHEMBL10063691 | 0.79 | CSNK2A2 (0.41) | SLC22A12GRIA2GRIA4CSNK2A2CSNK2B | |
| SCHEMBL16502450 | 0.79 | BCL2L1 (0.50) | BCL2L1BADNR4A2CSNK2A2CSNK2B | |
| SCHEMBL16502443 | 0.78 | SLC22A12 (0.56) | SLC22A12XDHNR3C2GRIA2GRIA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120041036-A1 | SUBSTITUTED ACYLGUANIDINE DERIVATIVES (AS AMENDED) | ASTELLAS PHARMA INC. (JP) | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120041036-A1 | SUBSTITUTED ACYLGUANIDINE DERIVATIVES (AS AMENDED) | HTR5A, HTR2A, HTR1A | BCL2L1 1044/4885BAD 109/4885SLC22A12 1219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.